Coming out of COVID19 – 2023 is expected to see increased pressures on pharma due to cost and supply chain, but also presents plenty of opportunities to innovate with the advent of new modalities, AI, automation. It is also a pivotal year with Annex 1 being enforced and an increased focus on growth and profit […]

SciMed will be participating in the upcoming PDA Asia Pacific two-day workshop, focusing on the significant changes outlined in the final version of Annex 1. This workshop is crucial for practitioners, consultants, and suppliers who need to understand and prepare for these changes. By attending this workshop: delegates will acquire insights from regulators involved in […]